PMID- 1694911
OWN - NLM
STAT- MEDLINE
DCOM- 19900816
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 15
IP  - 6
DP  - 1990 Jun
TI  - Negative inotropic properties of isradipine, nifedipine, diltiazem, and verapamil 
      in diseased human myocardial tissue.
PG  - 892-9
AB  - We investigated the inotropic responses to Ca2+ antagonists using electrically 
      driven human papillary muscle strips and human auricular trabeculae. Specimens 
      were obtained during cardiac surgery for mitral valve replacement [New York Heart 
      Association (NYHA) Class II-III] or heart transplantation (NYHA IV) and during 
      aortocoronary bypass operations. The inotropic effects were studied with 
      cumulative concentration-response curves. All Ca2+ antagonists tested 
      significantly (p less than 0.05) depressed force of contraction at concentrations 
      above 0.01 mumol/L, but their potencies were different. A 50% reduction of the 
      initial force of contraction occurred at the following concentrations (NYHA 
      II-III): nifedipine (mean IC50) 0.09 mumol/L isradipine 0.12 mumol/L, diltiazem 
      0.69 mumol/L, and verapamil 0.79 mumol/L. There were no significant differences 
      in the negative inotropic effects of any tested Ca2+ antagonist between NYHA 
      II-III and NYHA IV. When the initial force of contraction was reduced by 90%, 
      addition of Ca2+ increased force of contraction significantly less after 
      diltiazem (2.76 +/- 0.4 mN), isradipine (1.82 +/- 0.23 mN), and nifedipine (1.68 
      +/- 0.25 mN) compared to control (4.63 +/- 0.56 mN) (NYHA II-III). The negative 
      inotropic potencies of nifedipine and verapamil were significantly greater in 
      human auricular trabeculae compared to papillary muscle strips (p less than 
      0.05). However, on the relation between therapeutic vasoactive plasma 
      concentrations and IC25 values, an entirely different rank order of potential 
      negative inotropism could be observed: verapamil greater than nifedipine greater 
      than diltiazem greater than isradipine.
FAU - Schwinger, R H
AU  - Schwinger RH
AD  - Medizinische Klinik I Universitat Munchen, Federal Republic of Germany.
FAU - Bohm, M
AU  - Bohm M
FAU - Erdmann, E
AU  - Erdmann E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Pyridines)
RN  - CJ0O37KU29 (Verapamil)
RN  - EE92BBP03H (Diltiazem)
RN  - I9ZF7L6G2L (Nifedipine)
RN  - M4I0D6VV5M (Calcium Chloride)
RN  - YO1UK1S598 (Isradipine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Calcium Channel Blockers/*pharmacology
MH  - Calcium Chloride/pharmacology
MH  - Diltiazem/pharmacology
MH  - Electric Stimulation
MH  - Female
MH  - Heart/*drug effects/physiopathology
MH  - Heart Diseases/*physiopathology
MH  - Humans
MH  - In Vitro Techniques
MH  - Isradipine
MH  - Male
MH  - Middle Aged
MH  - Myocardial Contraction/*drug effects
MH  - Nifedipine/pharmacology
MH  - Papillary Muscles/drug effects
MH  - Pyridines/pharmacology
MH  - Verapamil/pharmacology
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
AID - 10.1097/00005344-199006000-00006 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1990 Jun;15(6):892-9. doi: 
      10.1097/00005344-199006000-00006.